Search

Displaying results 5011 - 5020 of 10000 in total
  1. Drug

    SLV-334

    go.drugbank.com/drugs/DB15356
    Investigational

    SLV-334 is under investigation in clinical trial NCT00735085 (A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury.).

  2. Drug

    Darapladib

    go.drugbank.com/drugs/DB06311
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  3. Drug

    Zuretinol acetate

    go.drugbank.com/drugs/DB12112
    Investigational

    Zuretinol acetate has been used in trials studying the treatment of Impaired Dark Adaptation, RP (Retinitis Pigmentosa), Retinitis Pigmentosa (RP), and LCA (Leber Congenital Amaurosis).

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    LY-2624803

    go.drugbank.com/drugs/DB15092
    Investigational

    LY-2624803 is under investigation in clinical trial NCT01236105 (Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject).

  5. Drug

    Velufenacin

    go.drugbank.com/drugs/DB21473
    Investigational

    Velufenacin has a monoisotopic molecular weight of 362.12 Da. … Velufenacin is a small molecule drug. The usage of the INN stem '-fenacin' in the name indicates that Velufenacin is a muscarinic receptor antagonist.

    Categories: Heterocyclic Compounds, 1-Ring
  6. Drug

    Remetinostat

    go.drugbank.com/drugs/DB14869
    Investigational

    Remetinostat is under investigation in clinical trial NCT02213861 (Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma).

  7. Drug

    R906289

    go.drugbank.com/drugs/DB19126
    Investigational

    R906289 is under investigation in clinical trial NCT05308264 (Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)).

  8. Drug

    Erfonrilimab

    go.drugbank.com/drugs/DB17446
    Investigational

    Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).

  9. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. … Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human

    Categories: Selective T Cell Costimulation Blocker, T Lymphocyte Costimulation Activity BlockadeProducts: NULOJIX ®250 MG/ VIAL POLVO LIOFILIZADO PARA SOLUCION INYECTABLE INTRAVENOSA
  10. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.